The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
01 吉利德科学公司宣布,美国FDA已授予Trodelvy突破性疗法认定,用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前,Trodelvy已在超过50个国家和地区获批,用于治疗经治转移性三阴性乳腺癌 ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
12月17日,翰森制药企业官微发布消息称,其合作方葛兰素史克(GSK)就GSK5764227 (GSK'227,亦称HS-20093)获得欧洲药品管理局 (EMA) 优先药物(PRIME)认定。
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...
【财华社讯】翰森制药(03692.HK)公布,GSK就GSK5764227(GSK’227,亦称 ...
安全审查委员会 (SRC)已确定REQORSA的推荐二期剂量 (RP2D)为0.12 mg/kg,这是一期试验中测试的最高剂量水平。二期扩展将在10至15个美国站点评估约50名患者的18周无进展生存率。尽管该股票显示出显著的波动性,beta值为-1.38,但分析师保持看涨观点,目标价为7.50美元。
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...
这是该产品在中国获批的第五项适应症,也是继鳞状非小细胞肺癌(sqNSCLC)、广泛期小细胞肺癌(ES-SCLC)后,该产品在肺癌领域获批的第三项适应症。
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...